Evolution from FNA to FNB
Evolution from FNA to FNB
Pancreatic cancer represents the fourth most common cause of cancer-related deaths
in Western countries, with a 5-year survival rate of 6 % [1]
[2]
[3].To improve treatment for these patients and to increase their survival, the need
for a low-risk investigation has become essential to obtain an accurate histopathological
diagnosis [4]. The standard method for sampling pancreatic masses is fine-needle aspiration (FNA)
performed under endoscopic ultrasonography (EUS) guidance. The sensitivity, specificity
and diagnostic accuracy of FNA for malignant cytological diagnosis have been reported
to range between 85 % to 95 %, 95 % to 98 % and 78 % to 95 %, respectively [5]
[6]. Several studies published in recent years aimed to identify factors related to
non-diagnostic or false-negative EUS-FNA sampling; moreover, to improve its diagnostic
yield, different sizes of needles and tissue acquisition (TA) techniques, such as
fanning technique, slow-pull stylet extraction or suction technique, have been implemented.
Despite data reporting a high sensitivity and specificity, more accurate diagnostic
results with EUS-FNA have been linked to the availability of rapid on-site evaluation
(ROSE). However, studies evaluating the diagnostic efficacy of EUS-FNA plus ROSE showed
a sensitivity and specificity of 83 % (95 %CI, 64 % to 93 %) and 98 % (95 %CI, 80 %
to 100 %), compared with 65 % (95 %CI, 57 % to 73 %) and 94 % (95 %CI, 31 % to 100 %)
when ROSE was not available [7]
[8]. Thus, no significant difference regarding diagnostic accuracy was found between
the two groups, with no clear benefit from the use of ROSE. Recently, a systematic
review with meta-analysis evaluated the pooled diagnostic accuracy of a repeat EUS-FNA
(rEUS-FNA) following a previous non-diagnostic result, demonstrating that rEUS-FNA
had an optimal pooled specificity (97 %) with high pooled sensitivity (78 %) for diagnosis
of pancreatic malignancies. In particular, the pooled sensitivity increased from 65 %
(95 %CI 57 – 73) without ROSE to 83 % (95 %CI 64 – 93) when ROSE was available, confirming
the beneficial role of ROSE in this setting to increase the amount of definitive diagnoses
[9].
Another limit of EUS-FNA is that it does not allow to obtain a specimen adequate for
histological evaluation; therefore, for some pancreatic masses, such as in the presence
of autoimmune pancreatitis, a cytological examination obtained with FNA is of limited
value [10].
During recent years, there has been an increasing need to obtain histological specimens
during EUS procedures, rather than cytological samples, to guide oncological treatment
options. Therefore, the need for TA needles with different shapes and new configurations
has led to the concept of fine-needle biopsy (FNB). Several needles for FNB are available
with different design and technical features, such as needles with reverse bevel,
fork tip or Franseen tip. A histological specimen could avoid the need of a cytopathologist
in the endoscopic room, reducing procedures time, number of passes and additional
costs of a possible repeated EUS-FNA, in case of an inconclusive diagnosis.
Is FNB better than FNA?
Different articles comparing FNA vs FNB have been published in recent years. Recently,
in a prospective comparison study, conducted in a consecutive cohort of 36 patients
affected by pancreatic cancer who underwent EUS-TA with 22 G FNA and 22 G FNB, Tian
et al. showed that the number of passes needed to obtain a diagnosis was significantly
lower for patients who underwent EUS-FNB (1.11 vs 1.83); in particular, the proportion
of diagnoses of malignancies obtained with just one needle pass were significantly
higher in the FNB group (80 % vs 66.67 %) [11].
Recently, promising results have been reported by a randomized controlled trial, analyzing
tissue and molecular diagnostic yield of FNA and FNB. Comparing the two techniques,
median total tissue area for each specimen was significantly higher for FNB (1.9 vs
5.2 mm2), with a consequent higher on-site diagnostic rate. One of the most important novelties
arising from this study was that quantification of nucleic acid obtained from the
samples was higher in patients who underwent FNB compared to FNA, regarding both DNA
and RNA extraction. Indeed, EUS-FNB can obtain more tissue with higher content of
nucleic acid allowing downstream genomics applications such as nucleotide genomic
sequence assay (NGS). Because it is a convenient and safe method for obtaining tumor
samples for genetic analysis, EUS-FNB could play a pivotal role in guiding new genomics
therapies [12].
Other comparative studies showed similar results, in terms of fewer needle passes
required to achieve adequate samples and more core TA with a single pass in favor
of FNB. A recent retrospective study from Varadarajulu et al., which included more than 3000 patients, showed that significantly fewer passes were
needed to obtain a correct diagnosis using FNB compared to FNA (1 vs 2; P < 0.001), with an increased diagnostic yield on cell-block using FNB (92.3 % vs 71.1 %;
P < 0.001) and an overall superior performance for pancreatic lesions (P < 0.001) [13].
On the basis of the available literature, FNB has shown a diagnostic yield of more
than 90 % [14]. Moreover, the diagnostic performance of FNB sampling of pancreatic masses was significantly
better than FNA sampling, and was also associated with ease of diagnosis and shorter
viewing times by the pathologists [15]. As a result, presence of an onsite cytopathologist is not required during EUS-FNB
sampling, reducing the overall duration of the procedures.
Similar results in terms of diagnostic yield and specimen adequacy for a correct diagnosis
were also reported with use of 25 G needles compared to larger ones; however, despite
the high diagnostic yield of 25 G needles, the smaller samples obtained with these
needles could represent a limit considering advances in new oncological and molecular
discoveries related to pancreatic cancer [16].
In the near future, FNA needles will probably be used only for selected cases, such
as patients with complex anatomy or with a high risk of bleeding (portal hypertension,
coagulopathies, and deep arterial or venous thrombosis). FNA needles could also be
used for therapeutic EUS procedures, such as contrast injection into the pancreatic
or bile ducts, release of a guide-wire, or injection therapies [17].
Which size needle should be used to sample pancreatic masses?
Which size needle should be used to sample pancreatic masses?
The two most important variables influencing the diagnostic accuracy of EUS-TA of
pancreatic masses are the type of needle (FNA and FNB), as previously discussed, and
the size (19G, 20G, 22 G or 25 G). Several types and designs of FNB needles are currently
available [18]. The first FNB needle was launched in 2011 (ProCore – Wilson-Cook Medical Inc.,
United States); its main characteristic was the distal reversed bevel design and different
sizes of needles were available for sampling: 19 G, 22 G and 25 G. A second-generation
20 G needle with a proximal forward bevel design and “Menghini” tip type was launched
in 2015: the EchoTip ProCore HD Ultrasound Biopsy Needle (Wilson-Cook Medical Inc.,
United States).
Recently, two different types of FNB needles have been introduced in clinical endoscopic
practice: one with fork-tip design (SharkCore, Medtronic, Minneapolis, Minnesota,
United States), and another with Franseen tip design (Acquire, Boston Scientific,
Natick, Massachusetts, United States). A large network meta-analysis from Facciorusso
et al. compared different sizes and types of needles for EUS tissue-acquisition, evaluating
a total of 2711 patients. The meta-analysis showed that no EUS-guided tissue sampling
technique was superior to another, regardless of needle type (FNA vs FNB) or size
(19 G vs 22 G vs 25 G). Moreover, no difference was found between 25G FNA and 22G
FNA needles (relative risk [RR], 1.03; 95 % confidence interval [CI], 0.91 – 1.17)
and between 22 G FNB and 22 G FNA needles (RR, 1.03; 95 % CI, 0.89 – 1.18) in terms
of diagnostic accuracy, sample adequacy and histologic core procurement [19].
Diagnostic performance of the 20G Procore FNB needle was evaluated in a prospective,
randomized, multicenter clinical trial compared to the 25 G FNB needles for sampling
of solid pancreatic lesions. This study included 88 patients and showed a significantly
higher procurement rate of core biopsy specimens among the 20G FNB needle group (41/45,
91.1 %) compared to the 25G FNB needle group (32/43, 74.4 %, P = 0.037). No significant differences were observed in the overall diagnostic accuracy
between the 20 G FNB needle (40/45, 88.9 %) and the 25 G FNB (34 /43, 79.1 %, P = 0.208). Therefore, although both FNB needles provided high overall diagnostic accuracy,
the reliability of the 20 G FNB needle was superior to the 25 G FNB when retrieving
samples for histological analysis [19], and should be preferred when sampling pancreatic masses.
A recent observational study comparing the 20G Procore vs the 22 G Acquire needles
for EUS-FNB of solid pancreatic masses, conducted on 68 patients, showed that histological
diagnosis on core biopsy specimens was obtained in 28 of 34 patients (82 %) in the
20 G group and in 33 of 34 patients (97 %) in the 22G group (P = 0.1). Mean cumulative length of tissue core biopsies per needle pass was significantly
higher with the 22G needle with 8.2 ± 4.2 mm versus 4.2 ± 3.8 mm for the 20 G needle
(P < .01), in the absence of intraobserver and inter-observer variability [21]. In our opinion, thinner needles (22 G vs. 20 G) may be easier to maneuver, especially
during EUS-FNB of pancreatic masses in the head or the uncinate process, and the EUS
scope is bent into the duodenum. Several new TA needles currently exist and none of
them has shown a significant superiority in prospective controlled trials. The aim
of EUS sampling should be to obtain an adequate sample for diagnosis in more than
90 % of cases, and allow to performance of immunohistochemistry and evaluation of
tumor markers, if necessary, to ensure the most appropriate oncological treatment
for patients ([Fig. 1]).
Fig. 1 Specimen of a solid pancreatic mass obtained after two passes with a 22G FNB needle.
Is on-site evaluation necessary during FNB procedures?
Is on-site evaluation necessary during FNB procedures?
As previously reported, in some settings, such as during repeat EUS-FNA, ROSE can
increase diagnostic accuracy. To evaluate its role during FNB sampling, a multicenter,
randomized, non-inferiority trial was conducted in 16 international centers, including
a large prospective cohort of patients. The authors randomized 800 patients with solid
pancreatic masses to sampling with EUS-FNB plus ROSE or EUS-FNB alone, demonstrating
the non-inferiority of FNB alone [22].
With the advent of FNB, macroscopic on-site evaluation (MOSE) of the specimen by the
endosonographer has been proposed as an alternative to ROSE [23]
[24]. A recent retrospective study including a cohort of 54 patients who underwent TA
with a 22G Franseen-tip needle, showed an overall diagnostic accuracy of 94 % adding
MOSE to the FNB sampling. Moreover, the reported sensitivity, specificity, positive
predictive value, and negative predictive value for malignancy were 92 %, 100 %, 100 %,
and 81 %, respectively, with no adverse events [25].
Which acquisition technique should be used for sampling pancreatic masses?
Which acquisition technique should be used for sampling pancreatic masses?
Techniques for specimen acquisition
There is no a standard technique for TA both for FNA and FNB. Different features influence
the acquisition technique, such as the size of the pancreatic lesion, its location,
the size and type of needle, and the availability of the ROSE [26]
[27]
[28].
Three main techniques have been described, and endosonographers usually choose which
technique to use based on their personal experience. The first technique to have been
described was the standard suction technique (SST). Briefly, after the needle tip
is placed inside the target lesion, the stylet is pulled-back completely and a syringe,
with high negative pressure, is mounted on the handle of the needle. The suction induced
by the negative pressure facilitates entry of tissue into the needle. This technique
is generally used for FNA but may damage the cellular structure of the tissue and
cause considerable blood contamination of the specimen [29].
The second technique is the stylet slow-pull (SSP) technique. While the endosonographer
performs to-and-fro movements with the needle inside the lesion, the stylet is slowly
removed to create negative pressure, which allows the tissue to enter the needle [30]
[31]. The low negative pressure induced by slowly removing the stylet avoids damaging
the specimen [32] and reduces blood contamination of the sample [33]
[34]
[35].
The third is the non-suction technique (NST) after stylet removal. After puncturing
the targeted lesions, the stylet is completely removed and the needle is moved to-and-fro
within the lesion, without a negative pressure syringe mounted onto the needle handle
[36].
Recently, the three TA techniques were compared in a cohort of 50 patients, without
using ROSE. The study showed that the rate of a good or excellent proportion of cellularity
in the sample was highest when the SSP technique was used compared to the standard
suction and non-suction techniques (SSP 72 % vs SST 60 % vs NST 50 %, P = .049). A > 25 % rate of blood contamination was more prevalent in patients in which
TA was performed with the standard suction technique (SSP 30 % vs SST 42 % vs NST
10 %, P = .009). The rate of adequate core-TA was not significantly different among the three
groups (SSP 52 % vs SST 34 % vs NST 50 %, P = .140).
Use of the SSP technique and tumor size > 40 mm were favorable factors for diagnostic
adequacy [37].
Another TA technique has also recently been proposed, the wet-suction (WS) technique.
This technique, rarely used, consists on irrigating the needle with saline solution
to replace the air. The saline solution, being liquid, is less compressible than air,
allowing better transmission of the negative pressure to the tip of the needle [38]. A RCT compared the WS to the standard suction technique during EUS-FNA in patients
with solid masses and showed that WS improved both sample adequacy and quality [39].
Techniques for targeting lesions
Different techniques have been proposed for targeting lesions during TA. The standard
technique (ST) consists of placing the tip of the needle within the lesion, moving
the needle to-and-fro on the same axis, regardless of the TA technique applied (standard
suction, slow-pull, wet or non-suction technique).
Two other techniques, the fanning technique (FT) and the torque technique (TT), have
been proposed to establish accurate diagnosis with fewer needle passes, resulting
in shorter procedure duration and lower sedation requirement to carry out the procedure.
FT consists of placing the needle in four different areas of the lesion by using the
“up-down” wheel of the scope, applying to-and-fro movements four times in each area
to procure tissue (4 × 4). This technique was initially proposed by Bang et al. who
conducted a RCT comparing the two techniques. No significant differences were found
regarding diagnostic accuracy (76.9 % vs. 96.4 %; P = 0.05), technical failure, or complication rates; however, there was a significant
difference between the ST and FT in both the number of passes needed to establish
a diagnosis and the percentage of patients in whom a diagnosis was achieved with the
first needle pass (57.7 % vs. 85.7 %; P = 0.02) [40].
During the TT, the needle is first advanced into the lateral margin of the targeted
lesion. Then, the operator performs repetitive to-and-fro movements while twisting
the endoscope without using the left/right wheel. This technique was recently compared
to the ST, showing significant differences between the groups regarding the procurement
rate for the histologic cores and optimal quality cores (ST vs TT: 87.1 % vs 98.4 %,
P = 0.038 and 79.0 % vs 93.5 %, P = 0.037). Sensitivity, specificity, positive predictive value, and negative predictive
values for EUS-FNB were 85.5 %, 100 %, 100 %, and 46.7 %, respectively, using the
ST, and 96.5 %, 100 %, 100 %, and 71.4 % for the TT. Diagnostic accuracy of the ST
and TT was 87.1 % and 96.8 %, respectively. In conclusion, the TT for EUS-TA offered
acceptable technical feasibility and superior diagnostic performance, including optimal
histologic core procurement, compared with the ST [41]. No study comparing the FT vs TT has yet been published. Nevertheless, most endosonographers
combine these three techniques based on their personal experience and on the characteristic
of the lesion being targeted.
Conclusions
On the basis of the published data, FNB has proven to be superior to FNA for EUS-TA
of pancreatic masses, as it makes it possible to obtain histological specimens that
do not require ROSE, reducing the number of needle passes and procedure duration.
FNB 22G needles seem to be the best option for sampling pancreatic masses, however,
25G needles can be used for challenging targets, such as small or hypervascular lesions.
The fanning technique should be used to obtain specimens from different areas of the
target lesion, and the stylet slow-pull technique also should be used to apply a low
negative pressure, avoiding fragmentation of the specimen. Finally, FNB-acquired specimens
should be evaluated by MOSE to limit needle passes ([Fig. 2]).
Fig. 2 Algorithm for diagnosis of pancreatic masses.
